Therapeutic applications of CRISPR /Cas9 gene editing technology for the treatment of ocular diseases
The FEBS Journal · 2023-11 · 290 (22) · 5248-5269
DOI: 10.1111/febs.16771 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FEBS Journal, online erschienen am 27.03.2023. Verfasst von Yogapriya Sundaresan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Neuroscience, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS, National Eye Institute.
Abstract (Originalsprache)
Ocular diseases are a highly heterogeneous group of phenotypes, caused by a spectrum of genetic variants and environmental factors that exhibit diverse clinical symptoms. As a result of its anatomical location, structure and immune privilege, the eye is an ideal system to assess and validate novel genetic therapies. Advances in genome editing have revolutionized the field of biomedical science, enabling researchers to understand the biology behind disease mechanisms and allow the treatment of several health conditions, including ocular pathologies. The advent of clustered regularly interspaced short palindromic repeats (CRISPR)‐based gene editing facilitates efficient and specific genetic modifications in the nucleic acid sequence, resulting in permanent changes at the genomic level. This approach has advantages over other treatment strategies and is promising for the treatment of various genetic and non‐genetic ocular conditions. This review provides an overview of the CRISPR/CRISPR‐associated protein 9 (Cas9) system and summarizes recent advances in the therapeutic application of CRISPR/Cas9 for the treatment of various ocular pathologies, as well as future challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Neuroscience, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
ORCID-Profile: Gulab Zode
Förderung
- NEI NIH HHS
- National Eye Institute
Zitieren
APA
Sundaresan, Y., Yacoub, S., Kodati, B., Amankwa, C. E., Raola, A., & Zode, G. (2023). Therapeutic applications of CRISPR /Cas9 gene editing technology for the treatment of ocular diseases. The FEBS Journal, 290(22), 5248-5269. https://doi.org/10.1111/febs.16771
Vancouver
Sundaresan Y, Yacoub S, Kodati B, Amankwa CE, Raola A, Zode G. Therapeutic applications of CRISPR /Cas9 gene editing technology for the treatment of ocular diseases. The FEBS Journal. 2023;290(22):5248-5269. doi:10.1111/febs.16771
BibTeX
@article{Sundaresan2023,
author = {Sundaresan, Yogapriya and Yacoub, Sam and Kodati, Bindu and Amankwa, Charles E and Raola, Akash and Zode, Gulab},
title = {Therapeutic applications of CRISPR /Cas9 gene editing technology for the treatment of ocular diseases},
journal = {The FEBS Journal},
year = {2023},
volume = {290},
number = {22},
pages = {5248--5269},
doi = {10.1111/febs.16771}
}
EUVIMED